BRISTOL, Tenn., Dec. 10, 2014 /PRNewswire/ -- UPM
Pharmaceuticals, a division of Gregory Pharmaceutical Holdings,
Inc., has reached an agreement with BioPharmX, Inc. (OTCQB: BPMX)
to commercially manufacture solid dose iodine supplement tablets
for the consumer products sector. The tablets will be manufactured
at UPM's 475,000 square-foot manufacturing facility in Bristol, Tennessee, under a commercial supply
agreement. Terms of the agreement were not disclosed.
Dr. John M. Gregory, Chairman and
CEO of Gregory Pharmaceutical Holdings, Inc., said, "UPM's new
large-scale manufacturing facility and capabilities for solid dose
processing is an ideal setting for BioPharmX, which has a focus on
patented products in fast growing markets."
Anja Krammer, President of
BioPharmx, commented, "BioPharmX is impressed with UPM's customer
focus and agile responsiveness toward supporting outsourced
manufacturing needs, both critical elements to BioPharmX's
anticipated growth in the over-the-counter and dietary supplements
industry. We are excited about our planned product portfolio
and the near-term launch of our innovative iodine-based supplement,
where UPM will be an essential partner in meeting what we believe
will eventually be high-volume manufacturing requirements for
BioPharmX," continued Krammer.
About UPM Pharmaceuticals
UPM Pharmaceuticals, Inc. a
wholly owned division of Gregory Pharmaceutical Holdings, Inc., is
an independent drug development and contract manufacturer serving
the pharmaceutical and biotechnology industries. We provide
high-quality drug development services including formulation
development, cGMP clinical and commercial manufacturing, analytical
methods development and stability testing. UPM's clients enjoy
service that is customized and fast with total quality management
characteristics of a customer-focused business. Our history
includes successful collaborative interactions with small virtual
and large billion-dollar companies providing customized product
development services and solutions. UPM focuses on drug development
for dosages with oral routes of administration, in solid dosage
forms such as capsules and tablets, and semi-solid creams and
ointments. Our 475,000 square-foot commercial manufacturing
facility based in Bristol,
Tennessee allows us to serve our clients' needs from early
stage development to large-scale commercial production.
About BioPharmX Corporation
BioPharmX Corporation
(OTCQB: BPMX) is a Silicon Valley-based biotechnology company,
which seeks to provide innovative products through unique,
proprietary platform technologies for pharmaceutical,
over-the-counter ("OTC"), and dietary supplement applications in
the fast-growing health and wellness markets, including women's
health, dermatology, and otolaryngology (ears, nose &
throat). To learn more about BioPharmx, visit
www.biopharmx.com.
Forward-Looking Statements
Statements in this news
release relating to the business of BioPharmX, which are not
historical facts, are "forward-looking statements". These
forward-looking statements may be identified by words such as
"expect," "anticipate," "believe," or similar expressions that are
intended to identify such forward-looking statements. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement and the risks and other
factors detailed in the company's filings with the Securities and
Exchange Commission (SEC). Given these risks and uncertainties, you
are cautioned not to place undue reliance on such forward-looking
statements. The forward-looking statements included in this news
release are made only as of the date hereof and the company
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be required under
applicable securities law.
BioPharmX, the BioPharmX logo and "Biodelivery that makes a
difference" are registered trademarks of BioPharmX Corporation
Photo -
http://photos.prnewswire.com/prnh/20141209/163370LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/upm-pharmaceuticals-to-manufacture-biopharmxs-first-commercially-available-product-300007563.html
SOURCE UPM Pharmaceuticals, Inc.